Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Little Rock, Arkansas 72205


The purpose of this study is to evaluate the efficacy and safety of Thalidomide in patients with leukemia.

Study summary:

Patients will take Thalidomide tablets at bedtime daily until remission. The dose will be increased gradually and modified according to side-effects. The drug will be given daily up to the time of complete remission then as long as it is beneficial.


Inclusion Criteria: - Diagnosis of refractory or relapsed leukemia: acute leukemia, CML, CLLm and MDS. - Signed informed consent, including patient agreeing to use safe contraceptive methods during the treatment and for at least 4 months after the treatment is completed - Serum creatinine < or = 2.5mg/dL - Serum bilirubin< or = 2.5mg/dL - Negative pregnancy test - Age 18 years or older - Performance status < or = 3 Exclusion Criteria: - Pregnant or lactating women - Concurrent treatment with cytotoxic chemotherapy, or radiation - History of seizures, neurotoxicity, or active CNS disease - Serious infections not controlled by antibiotics



Primary Contact:

Principal Investigator
Barthel Barlogie, M.D., Ph.D.

Backup Contact:


Location Contact:

Little Rock, Arkansas 72205
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.